Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254670 | 0.79 | HDAC3 (0.91) | HDAC3GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL4373141 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A | |
| SCHEMBL18825687 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A | |
| SCHEMBL4369180 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A | |
| SCHEMBL18825664 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A | |
| SCHEMBL25222615 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A | |
| SCHEMBL4382929 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A | |
| SCHEMBL5634680 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A | |
| SCHEMBL10353082 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A | |
| SCHEMBL18825661 | 0.79 | GAA (0.59) | HPGDHDAC3GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105597-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2011-05-05 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20100280036-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20090076012-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214635-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080194588-A1 | Modulation of pathogcnicity | QUONOVA, LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194607-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080194607-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-14 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188536-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188491-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080188535-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-08-07 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182878-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-20080176938-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2008-07-24 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335779-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194588-A1 | Modulation of pathogcnicity | NR4A1, NR4A2, NR3C2 | HPGD 1157/4885HDAC3 1216/4885GAA 4075/4885 |
| US-20090076012-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | HPGD 2540/4885HDAC3 1511/4885GAA 3227/4885 |
| US-20110105597-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885 |
| US-20080214635-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885 |
| US-20100280036-A1 | Modulation of Pathogenicity | NR4A1, NR4A2, NR4A3 | HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885 |
| US-20080182878-A1 | Modulation of pathogenicity | NR4A1, NR4A2, MSR1 | HPGD 2561/4885HDAC3 1498/4885GAA 3223/4885 |
| US-20080188491-A1 | Modulation of pathogenicity | NR4A1, MSR1, NR4A2 | HPGD 2727/4885HDAC3 1418/4885GAA 3503/4885 |
| US-20080194607-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885 |
| US-20080188535-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885 |
| US-20080188536-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | HPGD 2583/4885HDAC3 1483/4885GAA 3234/4885 |
| US-20080176938-A1 | Modulation of pathogenicity | NR4A1, NR4A2, NR4A3 | HPGD 2629/4885HDAC3 1563/4885GAA 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.